DK1991584T3 - Antistoffer mod human IL-22 og anvendelser deraf - Google Patents

Antistoffer mod human IL-22 og anvendelser deraf

Info

Publication number
DK1991584T3
DK1991584T3 DK07751204.4T DK07751204T DK1991584T3 DK 1991584 T3 DK1991584 T3 DK 1991584T3 DK 07751204 T DK07751204 T DK 07751204T DK 1991584 T3 DK1991584 T3 DK 1991584T3
Authority
DK
Denmark
Prior art keywords
antibodies
human
Prior art date
Application number
DK07751204.4T
Other languages
English (en)
Inventor
Jing Li
Davinder S Gill
Geertruida M Veldman
Lynette A Fouser
Viia Valge-Archer
David C Lowe
Caroline S Russell
Suzanne E Cohen
Albert B Thom
Ralph R Minter
Original Assignee
Wyeth Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1991584(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK1991584T3 publication Critical patent/DK1991584T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK07751204.4T 2006-02-21 2007-02-21 Antistoffer mod human IL-22 og anvendelser deraf DK1991584T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77459606P 2006-02-21 2006-02-21
PCT/US2007/004430 WO2007098170A1 (en) 2006-02-21 2007-02-21 Antibodies against human il-22 and uses therefor

Publications (1)

Publication Number Publication Date
DK1991584T3 true DK1991584T3 (da) 2012-04-02

Family

ID=38236225

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07751204.4T DK1991584T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human IL-22 og anvendelser deraf
DK15184078.2T DK3020729T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human il-22 og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15184078.2T DK3020729T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human il-22 og anvendelser deraf

Country Status (32)

Country Link
US (4) US7901684B2 (da)
EP (3) EP1991584B1 (da)
JP (1) JP5150516B2 (da)
KR (2) KR101616712B1 (da)
CN (1) CN101426816B (da)
AR (1) AR059604A1 (da)
AT (1) ATE538137T1 (da)
AU (1) AU2007217751B2 (da)
BR (1) BRPI0708101B8 (da)
CA (1) CA2643226C (da)
CR (1) CR10237A (da)
DK (2) DK1991584T3 (da)
EC (1) ECSP088751A (da)
ES (2) ES2738731T3 (da)
HK (1) HK1120813A1 (da)
HN (1) HN2008001292A (da)
HU (1) HUE044595T2 (da)
IL (1) IL193605A (da)
MX (2) MX2008010708A (da)
MY (1) MY146664A (da)
NO (1) NO20083715L (da)
NZ (1) NZ570878A (da)
PE (1) PE20080111A1 (da)
PL (2) PL1991584T3 (da)
PT (2) PT3020729T (da)
RU (1) RU2467016C2 (da)
SA (1) SA07280062B1 (da)
SG (1) SG172628A1 (da)
SI (2) SI3020729T1 (da)
TW (1) TWI417301B (da)
WO (1) WO2007098170A1 (da)
ZA (1) ZA200807278B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000065027A2 (en) * 1999-04-28 2000-11-02 Genetics Institute, Inc. Human gil-19/ae289 proteins and polynucleotides encoding same
BRPI0619118A2 (pt) * 2005-12-02 2011-09-13 Genentech Inc composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP2337799A2 (en) * 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2011022093A2 (en) 2009-04-13 2011-02-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and devices for detecting the presence of an analyte in a sample
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
CN102652259B (zh) 2010-03-12 2016-07-27 小利兰·斯坦福大学托管委员会 基于磁性传感器的定量结合动力学分析
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9221904B2 (en) * 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
AU2013310924B2 (en) * 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
KR102426481B1 (ko) 2013-03-15 2022-07-27 제넨테크, 인크. IL-22 폴리펩티드 및 IL-22 Fc 융합 단백질 및 사용 방법
CN105139918B (zh) * 2015-06-26 2017-04-12 哈尔滨工业大学 一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
BR112019008265A2 (pt) 2016-11-28 2019-07-09 Chugai Pharmaceutical Co Ltd molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
EP3719035A4 (en) 2017-11-28 2021-09-01 Chugai Seiyaku Kabushiki Kaisha POLYPEPTIDE INCLUDING AN ANTIGEN BINDING DOMAIN AND A TRANSPORT SECTION
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
CN112292396A (zh) 2018-06-05 2021-01-29 生物蛋白有限公司 抗il-22抗体，抗体片段，其免疫结合物及其用途
WO2020076453A1 (en) 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
AR124250A1 (es) 2020-12-07 2023-03-01 UCB Biopharma SRL Anticuerpos
CA3200847A1 (en) 2020-12-07 2022-06-16 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
EP4301777A1 (en) 2021-03-02 2024-01-10 Dana-Farber Cancer Institute, Inc. Methods of treating red blood cell disorders
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US20010006637A1 (en) * 1996-04-19 2001-07-05 Tohru Akahoshi Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
US6492507B1 (en) * 1996-10-23 2002-12-10 Incyte Genomics, Inc. Polynucleotides encoding human eosinophil-derived basic protein
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
PT1818343E (pt) * 1998-01-23 2012-07-12 Hoffmann La Roche Anticorpos contra a il-12 humana
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
EP1131333B1 (en) 1998-10-26 2010-06-02 Wyeth a Corporation of the State of Delaware ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CA2342967A1 (en) 1998-12-08 2000-06-15 Biovation Limited Modifying protein immunogenicity
TR200802278T2 (tr) 1999-03-25 2008-08-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
US7307161B1 (en) * 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AU5151100A (en) * 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
JP2003529324A (ja) 1999-06-15 2003-10-07 ジェネンテック・インコーポレーテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
EP1234035B1 (en) * 1999-12-03 2010-02-24 ZymoGenetics, Inc. Human cytokine receptor
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
MXPA02007291A (es) 2000-01-27 2002-11-29 American Cyanamid Co Metodo para preparar derivados de acido alfa-sulfonil hidroxamico.
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
CN101423551A (zh) 2000-07-27 2009-05-06 惠氏公司 分离的编码t细胞诱导因子或白介素-21的核酸分子，其编码的蛋白和其应用
US7094570B2 (en) * 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
BR0207528A (pt) 2001-02-23 2006-01-17 Inst Genetics Llc Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
WO2003083062A2 (en) * 2002-03-22 2003-10-09 Zymogenetics, Inc. Anti-il-tif antibodies and methods of using in inflammation
EP1534752B1 (en) * 2002-05-01 2011-08-03 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP2007537132A (ja) * 2003-06-23 2007-12-20 ジェネティクス インスティテュート，エルエルシー インターロイキン−２２に対する抗体およびその使用
WO2007004788A1 (en) 2005-07-04 2007-01-11 Samsung Electronics Co., Ltd. Position measuring system and method using wireless broadband (wibro) signal
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
PT1991584E (pt) 2012-02-20
EP3020729B1 (en) 2019-06-26
ES2738731T3 (es) 2020-01-24
PL1991584T3 (pl) 2012-05-31
ECSP088751A (es) 2008-11-27
EP1991584B1 (en) 2011-12-21
RU2467016C2 (ru) 2012-11-20
MY146664A (en) 2012-09-14
US7901684B2 (en) 2011-03-08
MX2008010708A (es) 2008-11-14
AU2007217751B2 (en) 2012-08-23
KR20140100589A (ko) 2014-08-14
RU2008134137A (ru) 2010-03-27
AR059604A1 (es) 2008-04-16
SA07280062B1 (ar) 2012-03-13
HK1120813A1 (en) 2009-04-09
MX337778B (es) 2016-03-18
CA2643226C (en) 2016-04-12
JP2009531023A (ja) 2009-09-03
IL193605A0 (en) 2011-08-01
US20130005033A1 (en) 2013-01-03
EP2431392B1 (en) 2015-09-09
DK3020729T3 (da) 2019-07-29
US8470993B2 (en) 2013-06-25
WO2007098170A1 (en) 2007-08-30
PL3020729T3 (pl) 2019-12-31
CN101426816A (zh) 2009-05-06
TWI417301B (zh) 2013-12-01
CA2643226A1 (en) 2007-08-30
SG172628A1 (en) 2011-07-28
US20070243589A1 (en) 2007-10-18
AU2007217751A1 (en) 2007-08-30
EP3020729A1 (en) 2016-05-18
PE20080111A1 (es) 2008-02-20
TW200801041A (en) 2008-01-01
CR10237A (es) 2008-11-26
BRPI0708101A2 (pt) 2011-05-17
BRPI0708101B8 (pt) 2021-05-25
BRPI0708101A8 (pt) 2019-01-22
EP1991584A1 (en) 2008-11-19
IL193605A (en) 2015-07-30
HN2008001292A (es) 2012-02-13
KR20080113214A (ko) 2008-12-29
SI3020729T1 (sl) 2019-10-30
ATE538137T1 (de) 2012-01-15
PT3020729T (pt) 2019-08-06
NO20083715L (no) 2008-11-06
HUE044595T2 (hu) 2019-11-28
KR101616712B1 (ko) 2016-04-29
US8182817B2 (en) 2012-05-22
JP5150516B2 (ja) 2013-02-20
SI1991584T1 (sl) 2012-05-31
ES2377463T3 (es) 2012-03-27
US8187603B2 (en) 2012-05-29
EP2431392A1 (en) 2012-03-21
ZA200807278B (en) 2009-05-27
CN101426816B (zh) 2012-12-12
US20110275790A1 (en) 2011-11-10
US20100184960A1 (en) 2010-07-22
BRPI0708101B1 (pt) 2020-01-14
NZ570878A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
DK1991584T3 (da) Antistoffer mod human IL-22 og anvendelser deraf
DK2129396T3 (da) Antistoffer mod ErbB3 og anvendelser deraf
DK3187506T3 (da) Antistoffer mod IL-6 og anvendelse deraf
DK2327423T3 (da) Humane antistoffer mod humant interleukin-22 (IL-22)
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK2474557T3 (da) Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
DK2220320T3 (da) Forseglet enhed og mellemstykke
DK1996621T3 (da) Antistoffer mod beta-amyloid-peptid
DK2913344T3 (da) Specifikke bindingsproteiner og anvendelser deraf
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
NO20080692L (no) SP35 antistoffer og anvendelse derav
DK1838733T3 (da) Antistoffer rettet mod angiopoietin-2 og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
DK2096167T3 (da) Aptamer mod midkin og anvendelse deraf